FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
Want to see FBLG full AI Analyst Report?
FBLG Stock Chart & Stats
$1.54
-$0.09(-3.98%)
At close: 4:00 PM EST
$1.54
-$0.09(-3.98%)
Day’s Range― - ―
52-Week Range$1.03 - $30.60
Previous CloseN/A
Volume56.64K
Average Volume (3M)978.93K
Market Cap
$5.41M
Enterprise Value$701.88K
Total Cash (Recent Filing)$4.89M
Total Debt (Recent Filing)$2.41M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
May 19, 2026EPS Estimate
-1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding3,512,845
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.51
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$4.75Price Target Upside208.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-4.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation And Pipeline ExpansionAnalyst states that initiation and interim and final readouts from the diabetic foot ulcer trial could validate the fibroblast platform, and regulatory filings for additional indications could expand clinical opportunities.
Preclinical EfficacyPreclinical studies reported faster and higher-quality wound healing with CYWC628 versus a market-leading graft and showed favorable inflammatory and cytokine changes in burn models, indicating potential clinical benefit.
Scientific RationaleAnalyst highlights that fibroblasts' central role in tissue repair and their use in existing graft products supports the scientific basis for the CYWC628 therapy, reinforcing confidence in the approach.
Bears Say
Clinical Execution RiskAnalyst identifies uncertainty around the diabetic foot ulcer trial's start, manufacturing completion, and patient enrollment as a material operational risk for program timelines.
Financing RiskAnalyst expects the company will need to raise additional capital, which could pressure financial forecasts and lead to shareholder dilution.
FibroBiologics, Inc. News
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $1.03 and its highest was $30.60 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $5.41M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is May 19, 2026 which is in 32 days.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Apr 06, 2026. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.44 by $0.44.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate is -1.33.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 3,512,845 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$1 in its last earnings report, beating expectations of -$1.44. Following the earnings report the stock price went up 3.65%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Currently, no hedge funds are holding shares in FBLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
$4.75
▲(208.44% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Curis
―
Synlogic
―
Lexaria Bioscience
―
Processa Pharmaceuticals
―
Ownership Overview
9.27% Insiders
1.95% Mutual Funds
1.45% Other Institutional Investors
85.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---